Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Rhea-AI Summary

Astria Therapeutics (NASDAQ: ATXS) will present final Phase 1a data for STAR-0215 at the Eastern Allergy Conference in Palm Beach, Florida, on June 1, 2024. The focus will be on updated results for hereditary angioedema treatment. Jessica Best, VP of Medical Affairs, will present the poster at 9:45am EST.

Positive

• Presentation of final Phase 1a data indicates progress in clinical development.
• Participation in a reputable conference may enhance company visibility and credibility.
• Focus on hereditary angioedema treatment addresses a specific medical need.

Negative

• No mention of Phase 2 or further trials, which could imply delays or issues.
• Outcome of the Phase 1a trial not detailed, leaving efficacy and safety uncertain.
• Potential lack of immediate financial impact since the presentation is still in the early clinical phase.

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.

Jessica Best, Vice President of Medical Affairs at Astria Therapeutics, will present a poster titled, “Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema” at 9:45am EST on Saturday, June 1.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240524680301/en/

Astria:

Investor Relations and Media:

Elizabeth Higgins

investors@astriatx.com

Source: Astria Therapeutics, Inc.

FAQ

What is Astria Therapeutics presenting at the Eastern Allergy Conference?

Astria Therapeutics is presenting the final Phase 1a data for STAR-0215, focusing on hereditary angioedema treatment.

When and where will Astria Therapeutics present the Phase 1a data for STAR-0215?

Astria Therapeutics will present the data on June 1, 2024, at the Eastern Allergy Conference in Palm Beach, Florida.

Who will present Astria Therapeutics' data at the Eastern Allergy Conference?

Jessica Best, VP of Medical Affairs at Astria Therapeutics, will present the data.

What is STAR-0215 being developed for?

STAR-0215 is being developed for the treatment of hereditary angioedema.

What time will Astria Therapeutics present at the Eastern Allergy Conference?

The presentation will occur at 9:45am EST on June 1, 2024.